Stock ONCT ONCTERNAL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Oncternal Therapeutics, Inc.

Equities

ONCT

US68236P2065

Market Closed - Nasdaq
Other stock markets
 02:00:00 03/05/2024 am IST 		5-day change 1st Jan Change
8.745 USD +6.00% Intraday chart for Oncternal Therapeutics, Inc. +5.49% -18.45%
18/04 Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer CI
15/04 HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science
Oncternal Therapeutics, Inc. Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Traders Look Ahead to Flat Day After Post-Christmas Rally
Top Premarket Decliners
Sector Update: Health Care Stocks Stronger Late Afternoon
Sector Update: Health Care Stocks Steady Tuesday Afternoon
Oncternal Therapeutics Says One Patient Dies in Dose Expansion Phase 1/2 Trial of ONCT-808 for B-cell Lymphoma; Shares Fall
Oncternal Therapeutics, Inc. Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma
Oncternal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics, Inc. Adds Matthew Smith to its Prostate Cancer Scientific Advisory Board
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer
Oncternal Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Oncternal Therapeutics Says US FDA Greenlights Phase 1/2 Trial of Prostate Cancer Drug Candidate
Oncternal Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Study of ROR1 Targeting Autologous CAR T, ONCT-808, in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma
Oncternal Therapeutics, Inc. Announces Resignation of Gunnar Kaufmann as Chief Scientific Officer, Effective June 14, 2023
Oncternal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONCT Stock
  4. News Oncternal Therapeutics, Inc.
  5. Other languages